Fideuram Asset Management Ireland dac Makes New Investment in Boston Scientific Corporation $BSX

Key Points

• Fideuram Asset Management Ireland dac disclosed a new fourth-quarter position in Boston Scientific, buying 30,308 shares valued at about $3.1 million.
• Analysts remain broadly constructive on the stock, with a consensus rating of Moderate Buy and an average price target of $87.46, though some firms have recently cut targets or downgraded the shares.
• Boston Scientific reported solid quarterly results, beating EPS and revenue estimates, and its board authorized a $5 billion share buyback while insiders also added to their holdings.

Fideuram Asset Management Ireland dac purchased a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 30,308 shares of the medical equipment provider's stock, valued at approximately $3,118,000.

Other institutional investors have also added to or reduced their stakes in the company. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth about $26,000. United Community Bank boosted its holdings in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Colonial Trust Co SC boosted its holdings in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 231 shares in the last quarter. Finally, Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 142 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Argus raised Boston Scientific to a "strong-buy" rating in a report on Thursday, February 26th. Daiwa Securities Group cut Boston Scientific from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 29th. Sanford C. Bernstein restated an "outperform" rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Leerink Partners reduced their price objective on Boston Scientific from $87.00 to $74.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, UBS Group reduced their price objective on Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $87.46.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company's stock, valued at $776,057.76. This represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by corporate insiders.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Stock Down 2.7%

Shares of BSX stock opened at $49.12 on Friday. The stock has a 50 day moving average of $60.69 and a 200 day moving average of $78.84. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market cap of $73.01 billion, a P/E ratio of 20.55, a P/E/G ratio of 0.93 and a beta of 0.62. Boston Scientific Corporation has a twelve month low of $48.41 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific's quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 3.37 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.